Premium
Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy, Part II : Implementation
Author(s) -
Dunn Debra,
Ciccarelli Eileen,
Moltzen Nina
Publication year - 2019
Publication title -
aorn journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.222
H-Index - 43
eISSN - 1878-0369
pISSN - 0001-2092
DOI - 10.1002/aorn.12865
Subject(s) - hyperthermic intraperitoneal chemotherapy , cytoreductive surgery , medicine , peritoneal carcinomatosis , perioperative , surgical oncology , general surgery , intraperitoneal chemotherapy , ovarian cancer , surgery , perioperative nursing , colorectal cancer , cancer
Cytoreductive surgery ( CRS ) with hyperthermic intraperitoneal chemotherapy ( HIPEC ) is an extensive procedure used to treat peritoneal carcinomatosis, which is either primary or secondary to other cancers (eg, ovarian, colorectal, appendiceal) that have metastasized to the peritoneum. Morbidity, mortality, and quality of life have improved for patients selecting CRS with HIPEC as a cancer treatment. At Holy Name Medical Center in Teaneck, New Jersey, an interdisciplinary team was established to plan and coordinate performing this new procedure in the OR . The team created a written protocol for implementing CRS with HIPEC before patients were scheduled for surgery. This article explores the perioperative facets of implementing CRS with HIPEC and discusses care of the patient undergoing CRS with HIPEC , with a focus on perioperative nursing considerations.